Exploring the Potential of Traditional Herbs in the Management of
                    Diabetic Retinopathy: An Overview

Soumya Singh; Poonam Kushwaha; Sujeet Kumar Gupta

doi:10.1055/a-1148-3950

Drug Research, Table of Contents

Drug Res (Stuttg) 2020; 70(07): 298-309
DOI: 10.1055/a-1148-3950

Review

Exploring the Potential of Traditional Herbs in the Management of Diabetic Retinopathy: An Overview

Soumya Singh

¹Faculty of Pharmacy, Integral University, Lucknow, India

²Hygia Institute of Pharmaceutical Education and Research, Lucknow, India

,

Poonam Kushwaha

¹Faculty of Pharmacy, Integral University, Lucknow, India

,

Sujeet Kumar Gupta

²Hygia Institute of Pharmaceutical Education and Research, Lucknow, India

› Author Affiliations

Abstract

Diabetic retinopathy is a microvascular complication in diabetes that affects eyes and is responsible for most visual impairment in diabetic patients. Diabetic retinopathy affects up to 80% of those who have had diabetes for 20 years or more. At least 90% of new cases could be reduced with proper treatment and monitoring of the eyes. The longer a person has diabetes, the higher his or her chances of developing diabetic retinopathy. Hence, it compels need for its prevention and cure. There is an increasing interest in natural products in pharmacotherapy as the chemical diversity of natural products has better matches than the diversity of synthetic compounds. The current review summarises the potential of leading traditional herbs like Azadirachta indica, Ginkgo biloba, Anisodus tanguticus, Pinus pinaster, Salvia miltiorrhiza, Stephania tetrandra and Gymnema sylvestre in the management and potential reversal of DR-related pathogenesis. It also discusses the probable mechanism of actions, which are based on epidemiological, in-vitro and in-vivo studies carried out within past few years. [Graphical Abstract].

Graphical Abstract

Key words

diabetes mellitus - diabetic retinopathy - signalling mechanisms - traditional herbs

Full Text

References

References
1 Diabetic Retinopathy. Available at: https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611
2 Kumar B, Gupta SK, Nag TC. et al. Green tea prevents hyperglycaemia-induced retinal oxidative stress and inflammation in streptozotocin-induced diabetic rats. Ophthalmic Res 2012; 47: 103-8
3 Patel K, Srinivasan K. Plant foods in the management of diabetes mellitus: Vegetables as potential hypoglycaemic agents. Nahrung 1997; 41: 68-74
4 Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: Global prevalence, major risk factors, screening practices and public health challenges: A review. Clin Exp Ophthalmol 2016; 44: 260-77
5 Zheng L, Du Y, Miller C. et al. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 2007; 50(9): 1987-96
6 Acute-and-chronic-complications-of-diabetes. Available at: https:// www.diapedia.org/acute-and-chronic-complications-of-diabetes/7104343513/ pathophysiology -of -diabetic-retinopathy
7 Jeetah R, Bhaw-Luximon A, Jhurry D. Nanopharmaceutics: Phytochemical-based controlled or sustained drug delivery systems for cancer treatment. J Biomed Nanotechnol. 2014; 10: 1810-40
8 Simunovic MP, Maberley DA. Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: A systematic review and meta-analysis. Retina. 2015; 35: 10
9 Quresh M, Mark C. Gillies et al. Management of Diabetic Retinopathy: A Systematic Review. JAMA 2007; 298: 8
10 Mohammad SO, Mohd Imtiaz NM, Mairaj SS. et al. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. Journal of Diabetes and its Complications 2012; 26 (01) 56-64
11 Dal S, Sigrist S. The protective effect of antioxidants consumption on diabetes and vascular complications. Diseases 2016; 4: 24
12 Parveen A, Jin M, Kim SY. Bioactive phytochemicals that regulate the cellular processes involved in Diabetic nephropathy. Phytomedicine 2018; 39: 146-59
13 Hafsa J, Hammi K.M, Khedher MRB. et al. Inhibition of protein glycation, antioxidant and antiproliferative activities of Carpobrotusedulis extracts. Biomed Pharmacother 2016; 84: 1496-1503
14 Mishra B, Swaroop A, Kandpal RP. Genetic components in diabetic retinopathy. Indian J Ophthalmol 2016; 64: 55-61
15 Mohammad G, Kowlur RA. Diabetic retinopathy and signalling mechanism for activation of matrix metalloproteinase-9. J Cell Physiol 2012; 227: 1052-1061
16 Calderon GD, Juarez OH, Hernandez GE. et al. Oxidative stress and diabetic retinopathy: Development and treatment. Eye 2017; 31: 1122-30
17 Kumar B, Gupta SK, Saxena R. et al. Current trends in the pharmacotherapy of diabetic retinopathy 2012; 58 (02) 132-39
18 Li C, Miao X, Li F. et al. Oxidative stress-related mechanisms and antioxidant therapy in diabetic retinopathy. Oxidative Med Cell. Longev 2017; 9702820
19 Li HM, Kim JK, Jang JM. et al. Analysis of the inhibitory activity of Abeliophyllum distichum leaf constituents against aldose reductase by using high-speed counter current chromatography. Arch Pharm Res 2013; 36: 1104-12
20 Stitt A, Gardiner TA, Anderson NL. et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51 (09) 2826-32
21 Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H. et al. Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. Ophthalmology 2007; 114: 743-750
22 Vincent JA, Mohr S. Inhibition of Caspase-1/Interleukin-1β Signaling Prevents Degeneration of Retinal Capillaries in Diabetes and Galactosemia. Diabetes 2007; 56: 224-230
23 Craven PA, Studer RK, Felder J. et al. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 1997; 46: 671-681
24 Khan ZA, Chakrabarti S. Cellular signaling and poetntial new treatment targets for diabetic retinopathy. Exp Diab Res 2007; 31867: 1-12
25 Kowluru RA, Engerman RL, Case GL. et al. Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int 2001; 38: 385-90
26 Boeri D, Maiello M, Lorenzi M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 2001; 50: 1432-39
27 Joussen AM, Poulaki V, Le ML. et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18: 1450-52
28 Joussen AM, Poulaki V, Mitsiades N. et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-α suppression. FASEB J 2002; 16: 438-40
29 Huang Hu, Jarel KG, Zhong Xiufeng. et al. TNFα is required for late brb breakdown in diabetic retinopathy, its inhibition prevents leukostasis, protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci 2011; 52 (03) 1336-44
30 Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007; 95103: 1-14
31 Pari L, Uma MJ. Hypoglycaemic effect of Musa sapientum L. in alloxan-induced diabetic rats. J Ethnopharmacol 1999; 68: 321-325
32 Zhang LQ, Cui H. The clinical practice of Salvia miltiorrhiza in ophthalmology. Chin J Chin Ophthalmol 2005; 15 (04) 242-44
33 Safi SZ, Qvist R, Kumar S. et al. Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. BioMed Res Int 2014; 801269
34 Khalfaoui T, Basora N, Amel QM. Apoptotic factors (Bcl-2 and Bax) and diabetic retinopathy in type 2 diabetes. J Mol Hist 2010; 41: 143-52
35 Ellis D, Burgess PI, Kayange P. Management of Diabetic Retinopathy. Malawi Med J 2013; 25 (04) 116-120
36 Gond AK, Gupta SK. Diabetic retinopathy: Role of traditional medicinal plants in its management and their molecular mechanism. Int J Pharm Sci Invention 2016; 6 (06) 1-14
37 Chandira M, Jayakar BB. Formulation and evaluation of herbal tablets containing Ipomoea Digitata Linn. Extract. Int J Pharm Sci Rev and Res 2010; 3: 101-110
38 Gandhi J, Vrushabendra Swamy BM, Kotagiri S. et al. Indian medicinal plants with antidiabetic and related beneficial effects: A review. Res J Pharm Biol Chem Sci 2015; 6 (03) 31
39 Karmazyn M, Gan XT. Ginseng for the treatment of diabetes and diabetes-related cardiovascular complications: A discussion of the evidence. Canadian J Physio Pharmaco 2019; 97 (04) 265-276. https://doi.org/10.1139/cjpp-2018-0440
40 Han SY. et al. Component analysis and free radical-scavenging potential of Panax notoginseng and Carthamus tinctorius extracts. Chem Biodivers 2010; 7: 383-91
41 Fan Y, Qiao Y, Huang J. et al. Protective effects of panax notoginseng saponins against high glucose-induced oxidative injury in rat retinal capillary endothelial cells. Evid Based Complement Alternat Med 2016; 4: 5326382
42 Gao D, Guo Y, Li X. et al. An aqueous extract of Radix Astragali, Angelica sinensis, and Panax notoginseng is effective in preventing diabetic retinopathy. Evidence-Based Complementary and Alternative Medicine 2013;
43 Wang DD, Zhu HZ, Li SW. et al. Crude saponins of panax notoginseng have neuroprotective effects to inhibit palmitate-triggered endoplasmic reticulum stress-associated apoptosis and loss of postsynaptic proteins in staurosporine differentiated RGC-5 retinal ganglion cells. Agric. Food Chem 20166471528-1539.
44 Zhou L, Zuo Z, Chow MS. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics and clinical use. J Clin Pharmacol 2005; 45: 1345-59
45 Zhang L, Dai SZ., Nie XD. et al. Effect of Salvia miltiorrhiza on retinopathy. Asian Pacific Journal of Tropical Medicine 2013; 6 (02) 145-149
46 Zhang L. et al. Effect of Salvia miltiorrhiza on retinopathy. Asian Pac J Trop Med 2013; 6: 145-149
47 Wang Y, Ding L, Li Y. et al. Int J Clin Exp Med 2017; 10 (03) 5168-5174
48 Chen K. et al. Taurine protects transformed rat retinal ganglion cells from hypoxia-induced apoptosis by preventing mitochondrial dysfunction. Brain Res 2009; 1279: 131-138
49 Jeong J. et al. Taurine exerts neuroprotective effects via anti-apoptosis in hypoxic-ischemic brain injury in neonatal rats. Korean J Pediatr 2009; 52: 1337-1347
50 Zeng K. et al. Dietary taurine supple-mentation prevents glial alterations in retina of diabetic rats. Neurochem Res 2009; 34: 244-54
51 Yao Q, Yang Y, Lu X. et al. Lycium barbarum polysaccharides improve retinopathy in diabetic sprague-dawley rats. Evidence-Based Complementary and Alternative Medicine 2018;
52 Zhong Y. et al. Therapeutic use of traditional chinese herbal medications for chronic kidney diseases. Kidney Int 2013; 84: 1108-1118
53 Ding Y. Protective effects of astragaloside IV on db/db mice with diabetic retinopathy. PLoS One 2014; 9: e11220
54 Agyemang K. et al. Recent advances in Astragalus membranaceus antidiabetic research: pharmacological effects of its phytochemical constituents. Evid Based Complement Alternat Med 2013; 654643
55 Song MK, Roufogalis BD, Huang THW. Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology. Br J Pharmacol 2012; 165: 4-19 doi: 10.1111/j.1476-5381.2011. 01411.x
56 Eisenbrand G, Tang W. Anisodustanguticus (Max.) Pasch. In: Chinese Drugs of Plant Origin. Springer Berlin Heidelberg; 1992: 127–134
57 Shen X. et al. Effects of Scrophularia ningpoensis Hemsl. on inhibition ofproliferation, apoptosis induction and NF-jB signaling of immortalized and cancer cell lines. Pharmaceuticals (Basel) 2012; 5: 189-208
58 Yuan YZ, Yuan F, Xu QY. et al. Effect of Fufang Xueshuantong Capsule on a rat model of retinal vein occlusion. Chin J Integr Med 2011; 17: 296-301
59 Chen X, Yu J, Shi J. Management of diabetes mellitus with puerarin, a natural isoflavone from pueraria lobate. The American Journal of Chinese Medicine 2018; 46 (08) 1771-1789
60 Lim DW. et al. Effects of dietary isoflavones from Puerariae radix on lipid and bone metabolism in ovariectomized rats. Nutrients. 2013; 5: 2734-46
61 Zhou YX. et al. Puerarin: A review of pharmacological effects. Phytother Res 2014; 28: 961-975
62 Zhu X. et al. The effect of puerarin against IL-1b-mediated leukostasis and apoptosis in retinal capillary endothelial cells (TR-iBRB2). Mol Vis 2014; 20: 1815-1823
63 Kim JM. et al. Constituents of the roots of Pueraria lobata inhibit formation of advanced glycation end products (AGEs). Arch Pharm Res 2006; 29: 821-825
64 Isah T. Rethinking Ginkgo biloba L.: Medicinal uses and conservation. Pharmacogn Rev 2015; 9: 140-148
65 Brondino NA. Systematic review and meta-analysis of Ginkgo biloba in neuropsychiatric disorders: From ancient tradition to modern-day medicine. Evid Based Complement Alternat Med 2013; 915691
66 Berryman AM, Maritim AC, Sanders RA. et al. Influence of treatment of diabetic rats with combinations of Pycnogenol, beta-carotene, and alpha-lipoic acid on parameters of oxidative stress. J Biochem Mol Toxicol 2004; 18: 345-52
67 Ghattopadhyay RR. Possible mechanism of antihyperglycemic effect of Azadirachta indica leaf extract part 1V. Gen. Pharmacal Col. Letrs 1996; 27 (03) 431-34
68 Pillai N, Santha KG. Hypoglycaemic activity of Melia azasirachta. Ind. J Med Res 1981; 74: 931-33
69 Liang XC, Hagino N, Guo SS. et al. Therapeutic efficacy of Stephaniatetrandra S. Moore for treatment of neovascularization of retinal capillary (retinopathy) in diabetes – in vitro study. Phytomedicine 2002; 9 (05) 377-84
70 Fatani AJ, AlSS Rejaie, Abuohashish HM. et al. Neuroprotective effects of Gymnema sylvestre on streptozotocin induced diabetic neuropathy in rats. Exp Ther Med 2015; 9: 1670-78
71 Laha S, Paul S. Gymnema sylvestre (Gurmar): A potent herb with anti-diabetic and antioxidant potential. Pharmacog J 2019; 11 (02) 201-6
72 George P. Concerns regarding the safety and toxicity of medicinal plants - An overview. J App Pharm Sci 2011; 01: 40-44
73 Rowin J., Lewis S.L. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46: 1775-1776
74 Punnonen R., Lukola A. Estrogen-like effect of ginseng. Lancet 1980; 181: 1110
75 WHO-IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. (Some Traditional Herbal Medicines). Vol. 82, 2002 IARC Press Lyon, France.
76 World health organization. Adverse Drug Reaction Database. Uppsala Sweden. 36. Institute of Safe Medication Practices Medication Safety Alert. June 4 1997 V 01.2 No. ll.